Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma

Yun Hou, Hua Qing Wang, Kai Fu, Xian Ming Liu, Hui Lai Zhang, Zheng Zi Qian, Li Hua Qiu, Wei Li, Shi Yong Zhou, Lan Fang Li, Xi Shan Hao

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this study was to analyze the efficacy and toxicity of RNCE regimen in the treatment of relapsed or refractory B cell non-Hodgkin's lymphoma (NHL). Methods: From January 2000 to December 2005, 46 patients with relapsed or refractory B cell NHL were treated by RNCE regimen with or without radiotherapy for the involved field. The clinical characteristics, response, toxicity and long-term survival results were analyzed retrospectively. Results: A total of 46 patients were eligible. The complete response rate of second-line therapy was 52.17% (24/46), and the overall response rate was 82.61% (38/46). The median follow-up duration in this series was 69 months (range: 6 to 102 months). The overall 1, 3, 5-year survival rate was 74.8%, 48.3%, 40.1%, respectively, with a median survival time of 30.2 months (5 to 65 months), and median progression free survival time of 10.9 months (2 to 31 months). The major toxicities were myelosuppression, GI toxicity, fatigue, fever and alopecia. Conclusion: Our data show that RNCE regimen treatment is effective and well tolerated in patients with relapsed or refractory B cell non-Hodgkin's lymphoma.

Original languageEnglish (US)
Pages (from-to)306-310
Number of pages5
JournalChinese Journal of Oncology
Volume34
Issue number4
DOIs
StatePublished - Apr 23 2012

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Survival
Alopecia
Disease-Free Survival
Fatigue
Fever
Radiotherapy
Therapeutics
Survival Rate

Keywords

  • Drug resistance, neoplasm
  • Lymphoma
  • Non-Hodgkin
  • Recurrence
  • Rituximab
  • Treatment outcome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. / Hou, Yun; Wang, Hua Qing; Fu, Kai; Liu, Xian Ming; Zhang, Hui Lai; Qian, Zheng Zi; Qiu, Li Hua; Li, Wei; Zhou, Shi Yong; Li, Lan Fang; Hao, Xi Shan.

In: Chinese Journal of Oncology, Vol. 34, No. 4, 23.04.2012, p. 306-310.

Research output: Contribution to journalArticle

Hou, Yun ; Wang, Hua Qing ; Fu, Kai ; Liu, Xian Ming ; Zhang, Hui Lai ; Qian, Zheng Zi ; Qiu, Li Hua ; Li, Wei ; Zhou, Shi Yong ; Li, Lan Fang ; Hao, Xi Shan. / Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. In: Chinese Journal of Oncology. 2012 ; Vol. 34, No. 4. pp. 306-310.
@article{3b572480b55e4714bde4187eef337f2c,
title = "Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma",
abstract = "Objective: The aim of this study was to analyze the efficacy and toxicity of RNCE regimen in the treatment of relapsed or refractory B cell non-Hodgkin's lymphoma (NHL). Methods: From January 2000 to December 2005, 46 patients with relapsed or refractory B cell NHL were treated by RNCE regimen with or without radiotherapy for the involved field. The clinical characteristics, response, toxicity and long-term survival results were analyzed retrospectively. Results: A total of 46 patients were eligible. The complete response rate of second-line therapy was 52.17{\%} (24/46), and the overall response rate was 82.61{\%} (38/46). The median follow-up duration in this series was 69 months (range: 6 to 102 months). The overall 1, 3, 5-year survival rate was 74.8{\%}, 48.3{\%}, 40.1{\%}, respectively, with a median survival time of 30.2 months (5 to 65 months), and median progression free survival time of 10.9 months (2 to 31 months). The major toxicities were myelosuppression, GI toxicity, fatigue, fever and alopecia. Conclusion: Our data show that RNCE regimen treatment is effective and well tolerated in patients with relapsed or refractory B cell non-Hodgkin's lymphoma.",
keywords = "Drug resistance, neoplasm, Lymphoma, Non-Hodgkin, Recurrence, Rituximab, Treatment outcome",
author = "Yun Hou and Wang, {Hua Qing} and Kai Fu and Liu, {Xian Ming} and Zhang, {Hui Lai} and Qian, {Zheng Zi} and Qiu, {Li Hua} and Wei Li and Zhou, {Shi Yong} and Li, {Lan Fang} and Hao, {Xi Shan}",
year = "2012",
month = "4",
day = "23",
doi = "10.3760/cma.j.issn.0253-3766.2012.04.015",
language = "English (US)",
volume = "34",
pages = "306--310",
journal = "Chinese Journal of Oncology",
issn = "0253-3766",
publisher = "Chinese Academy of Medical Sciences",
number = "4",

}

TY - JOUR

T1 - Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma

AU - Hou, Yun

AU - Wang, Hua Qing

AU - Fu, Kai

AU - Liu, Xian Ming

AU - Zhang, Hui Lai

AU - Qian, Zheng Zi

AU - Qiu, Li Hua

AU - Li, Wei

AU - Zhou, Shi Yong

AU - Li, Lan Fang

AU - Hao, Xi Shan

PY - 2012/4/23

Y1 - 2012/4/23

N2 - Objective: The aim of this study was to analyze the efficacy and toxicity of RNCE regimen in the treatment of relapsed or refractory B cell non-Hodgkin's lymphoma (NHL). Methods: From January 2000 to December 2005, 46 patients with relapsed or refractory B cell NHL were treated by RNCE regimen with or without radiotherapy for the involved field. The clinical characteristics, response, toxicity and long-term survival results were analyzed retrospectively. Results: A total of 46 patients were eligible. The complete response rate of second-line therapy was 52.17% (24/46), and the overall response rate was 82.61% (38/46). The median follow-up duration in this series was 69 months (range: 6 to 102 months). The overall 1, 3, 5-year survival rate was 74.8%, 48.3%, 40.1%, respectively, with a median survival time of 30.2 months (5 to 65 months), and median progression free survival time of 10.9 months (2 to 31 months). The major toxicities were myelosuppression, GI toxicity, fatigue, fever and alopecia. Conclusion: Our data show that RNCE regimen treatment is effective and well tolerated in patients with relapsed or refractory B cell non-Hodgkin's lymphoma.

AB - Objective: The aim of this study was to analyze the efficacy and toxicity of RNCE regimen in the treatment of relapsed or refractory B cell non-Hodgkin's lymphoma (NHL). Methods: From January 2000 to December 2005, 46 patients with relapsed or refractory B cell NHL were treated by RNCE regimen with or without radiotherapy for the involved field. The clinical characteristics, response, toxicity and long-term survival results were analyzed retrospectively. Results: A total of 46 patients were eligible. The complete response rate of second-line therapy was 52.17% (24/46), and the overall response rate was 82.61% (38/46). The median follow-up duration in this series was 69 months (range: 6 to 102 months). The overall 1, 3, 5-year survival rate was 74.8%, 48.3%, 40.1%, respectively, with a median survival time of 30.2 months (5 to 65 months), and median progression free survival time of 10.9 months (2 to 31 months). The major toxicities were myelosuppression, GI toxicity, fatigue, fever and alopecia. Conclusion: Our data show that RNCE regimen treatment is effective and well tolerated in patients with relapsed or refractory B cell non-Hodgkin's lymphoma.

KW - Drug resistance, neoplasm

KW - Lymphoma

KW - Non-Hodgkin

KW - Recurrence

KW - Rituximab

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84862112619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862112619&partnerID=8YFLogxK

U2 - 10.3760/cma.j.issn.0253-3766.2012.04.015

DO - 10.3760/cma.j.issn.0253-3766.2012.04.015

M3 - Article

C2 - 22781046

AN - SCOPUS:84862112619

VL - 34

SP - 306

EP - 310

JO - Chinese Journal of Oncology

JF - Chinese Journal of Oncology

SN - 0253-3766

IS - 4

ER -